NGNE

Neurogene Inc. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website neurogene.com
Employees(FY) 82
ISIN US64135M1053

Performance

-61.67%

-71.82%

-57.19%

-53.98%

-20.9%

YTD

+16.14%

Profile

Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.

Advanced Technical Analysis

Technical Analysis of NGNE 2024-11-20

The stock indicators reflect a bearish sentiment, with the Moving Average Score at 10, Oscillators Score at 36, and a Technical Score of 23, indicating overall weakness in price momentum and suggesting caution for potential investors. The low scores across all categories highlight a lack of bullish signals in the current market environment.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of NGNE

Stock Rank

Recent News & Updates

2024-11-18 04:25
Neurogene Reports Third Quarter 2024 Financial Results and Highlights Recent Updates(Businesswire)
2024-11-18 03:14
How A Side Effect Has Wiped Out 73% Of Neurogene's Value In A Week(Yahoo Finance)
2024-11-17 20:48
Neurogene Down 36% Extends Losses After Side Effect Derails Its Rett Syndrome Drug(Yahoo Finance)
2024-11-17 17:45
Neurogene Provides Update on NGN-401 Gene Therapy Clinical Trial for Rett Syndrome(Businesswire)
2024-11-12 06:58
Neurogene Shares Drop 35% on Rett Syndrome Gene Therapy Trial Data(GuruFocus.com)
2024-11-12 03:10
Top Biotech Neurogene Crashes 44%, Wiping Out Its Sprint On A $200 Million Deal(Yahoo Finance)
2024-11-11 21:18
Top 1% Biotech Neurogene Crashes, Wiping Out A Run, On A Serious Side Effect(Yahoo Finance)
2024-11-11 16:01
Neurogene Reports Positive Interim Efficacy Data from First Four Low-Dose Pediatric Participants in NGN-401 Gene Therapy Clinical Trial for Rett Syndrome(Business Wire)
2024-11-11 03:01
Neurogene Reports Positive Interim Efficacy Data from First Four Low-Dose Pediatric Participants in NGN-401 Gene Therapy Clinical Trial for Rett Syndrome(Businesswire)
2024-11-04 18:54
Neurogene Secures $200M for Genetic Therapy Development(Yahoo Finance)
2024-11-04 07:30
Neurogene Announces Oversubscribed $200 Million Private Placement(Business Wire)
2024-11-03 18:30
Neurogene Announces Oversubscribed $200 Million Private Placement(Businesswire)
2024-10-21 07:30
Neurogene to Present Interim Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome(Business Wire)
2024-10-20 19:30
Neurogene to Present Interim Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome(Businesswire)
2024-08-17 10:01
Neurogene's (NASDAQ:NGNE) Earnings Might Be Weaker Than You Think(Simply Wall St.)
2024-08-09 07:30
Neurogene Reports Second Quarter 2024 Financial Results and Highlights Recent Updates(Business Wire)
2024-08-09 02:52
NGNE Stock Earnings: Neurogene Misses EPS for Q2 2024(Investorplace)
2024-08-08 19:30
Neurogene Reports Second Quarter 2024 Financial Results and Highlights Recent Updates(Businesswire)
2024-08-07 07:30
Neurogene Announces RMAT Designation for NGN-401 Investigational Gene Therapy for Rett Syndrome(Business Wire)
2024-07-02 07:30
Neurogene to Participate in BMO Genetic Medicines Summit(Business Wire)
2024-07-01 19:30
Neurogene to Participate in BMO Genetic Medicines Summit(Businesswire)
2024-07-01 07:30
Neurogene Announces Addition to Russell 3000Â® Index(Business Wire)
2024-06-30 19:30
Neurogene Announces Addition to Russell 3000 Index(Businesswire)
2024-06-18 21:23
Meridian Small Cap Growth Fund Trimmed Neurogene (NGNE) on Share Price Appreciation(Insidermonkey)
2024-06-18 09:26
Neurogene Announces First Patient Dosed in High-Dose Cohort of NGN-401 Gene Therapy Clinical Trial for Rett Syndrome(Business Wire)
2024-06-17 21:26
Neurogene Announces First Patient Dosed in High-Dose Cohort of NGN-401 Gene Therapy Clinical Trial for Rett Syndrome(Businesswire)
2024-06-05 07:30
Neurogene to Participate in Upcoming Conferences(Business Wire)
2024-06-04 19:30
Neurogene to Participate in Upcoming Conferences(Businesswire)
2024-06-03 07:30
Neurogene Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for START Pilot Program(Business Wire)
2024-06-02 19:30
Neurogene Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for START Pilot Program(Businesswire)

Page 1 of 2

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.